Yallaferon in Chinese Population

a Multi-sites, Randomized, Parallel, Placebo-Controlled Clinical, Pilot Study to Evaluated the Efficacy and Safety of Recombinant Human Interferon Alpha-2b Gel (Yallaferon®) in HPV Infection

The purpose of this study is to evaluate the efficacy of Yallaferon in Chinese population with HPV-16 and/or HPV-18.

Inclusion Criteria:

• Age 25 to 65 years of age the sex life of female patients;
• High-risk HPV 16 and/or 18 positive
• Agree to sign ICF

Exclusion Criteria:

• Cervical intraepithelial neoplasia (CIN);
• Combined with a severe fungal, trichomonas vaginitis;
• Severe primary diseases associated with cardiovascular, liver, kidney and hematopoietic system;
• Allergies or allergy to the drug known ingredients.
• Within 30 days to accept other clinical trials of drugs or are participating in clinical trials;
• Pregnant and lactating women and to be pregnant women;
• The researchers do not consider it appropriate clinical trials.